Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H40N2 |
| Molecular Weight | 356.5878 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1[C@H]2CC[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23CN1C)N(C)C
InChI
InChIKey=GPLGAQQQNWMVMM-MYAJQUOBSA-N
InChI=1S/C24H40N2/c1-16-20-8-9-22-19-7-6-17-14-18(25(3)4)10-12-23(17,2)21(19)11-13-24(20,22)15-26(16)5/h6,16,18-22H,7-15H2,1-5H3/t16-,18-,19+,20+,21-,22-,23-,24-/m0/s1
| Molecular Formula | C24H40N2 |
| Molecular Weight | 356.5878 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Conessine is a plant steroid alkaloid that acts as a potent and specific antagonist of histamine H3 receptors. Conessine displayed high affinity at both rat and human H3 receptors (pKi = 7.61 and 8.27) and generally high selectivity against other sites, including histamine receptors H1, H2, and H4. Conessine was found to efficiently penetrate the CNS and reach very high brain concentrations. Although the very slow CNS clearance and strong binding to adrenergic receptors discouraged focus on conessine itself for further development, its potency and novel steroid-based skeleton motivated further chemical investigation. Modification based on introducing diversity at the 3-nitrogen position generated a new series of H3 antagonists with higher in vitro potency, improved target selectivity, and more favorable drug-like properties. Conessine also has high affinity for the adrenergic receptors. Conessine has being shown to possess anti-malarial activity. In India conessine finds therapeutic use for treatment of dysentery and helminthic disorders.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL264 |
8.27 null [pKi] | ||
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18683917 |
6.18 null [pKi] | ||
Target ID: CHEMBL364 |
1.04 µM [IC50] | ||
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22569298 |
21.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. | 2015-07 |
|
| Acute cardiac toxicity of nerium oleander/indicum poisoning (kaner) poisoning. | 2010-10 |
|
| The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. | 2008-09-11 |
|
| Novel H3 receptor antagonists with improved pharmacokinetic profiles. | 2008-07-15 |
|
| Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells. | 2008-06-06 |
|
| Development and validation of a visible absorption densitometry method for quantitation of conessine in Holarrhena antidysenterica (Kurchi). | 2008-05-15 |
|
| A new family of H3 receptor antagonists based on the natural product Conessine. | 2008-02-15 |
|
| High-performance thin layer chromatography method for estimation of conessine in herbal extract and pharmaceutical dosage formulations. | 2008-01-22 |
|
| Chromatographic analysis of Kutajarista--an ayurvedic polyherbal formulation. | 2008-01-17 |
|
| Steroidal alkaloids from Holarrhena antidysenterica (L.) WALL. | 2007-06 |
|
| A new family of histamine H3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series. | 2007-04 |
|
| Antibacterial activities of the extracts and conessine from Holarrhena floribunda G. Don. (Apocynaceae). | 2007-02-16 |
|
| Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006-11 |
|
| Isolation, characterization and antiplasmodial activity of steroidal alkaloids from Funtumia elastica (Preuss) Stapf. | 2005-05-16 |
|
| Highly enantioselective construction of fused pyrrolidine systems that contain a quaternary stereocenter: concise formal synthesis of (+)-conessine. | 2004-05-03 |
|
| Steroid hormone activity of flavonoids and related compounds. | 2000-07 |
|
| Déjà vu guides the way to new antimicrobial steroid. | 1993-02-19 |
|
| Squalamine: an aminosterol antibiotic from the shark. | 1993-02-15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23758861
Mice: Conessine significantly reduced parasitaemia (at 10 mg/kg exhibited 88.95% parasite inhibition) in P. berghei-infected mice. Conessine was administered orally to mice of different groups for four days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23758861
Conessine showed in vitro anti-plasmodial activity with its IC₅₀ value 1.9 ug/ml and 1.3 ug/ml using schizont maturation and pLDH assay respectively. The compound showed cytotoxity IC₅₀= 14 ug/ml against L6 cells of rat skeletal muscle myoblast.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:44:33 GMT 2025
by
admin
on
Wed Apr 02 08:44:33 GMT 2025
|
| Record UNII |
EZ38J9BBDF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C221
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
27965
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
208-897-2
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
546-06-5
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
CHEMBL191703
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
EZ38J9BBDF
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
441082
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
SUB06803MIG
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
C007111
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
C79899
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
119994
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
CONESSINE
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
443
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
m3750
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID6046000
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY | |||
|
100000084247
Created by
admin on Wed Apr 02 08:44:33 GMT 2025 , Edited by admin on Wed Apr 02 08:44:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |